5-alpha reductase inhibitor slows progression of low-risk prostate cancer tumors

Active surveillance added to treatment with the 5-alpha reductase inhibitor dutasteride slowed the progression of cancerous prostate tumors in men with low-risk localized disease, according to researchers from the University of Toronto in Ontario, Canada.

Key Point: Active surveillance in combination with dutasteride is a reasonable strategy for the treatment of low-risk prostate cancer.

The World Health Organization’s International Agency for Research on Cancer estimated in its GLOBOCAN 2008 global report on cancer prevalence that about 14,000 cases of prostate cancer are diagnosed in India each year. As India continues to develop economically, it’s possible that this number could increase, because the rate of diagnosed prostate cancer cases is approximately 2 to 5 times higher in...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Oncology, Pharmacology, Urology and tagged , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.